101 assets in Exocrine Pancreatic Carcinoma

Therapeutic assets addressing Exocrine Pancreatic Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Sapanisertib Exocrine Pancreatic Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Surufatinib Exocrine Pancreatic Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Talazoparib Exocrine Pancreatic Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tamoxifen Exocrine Pancreatic Carcinoma	OHSU Knight Cancer Institute	P2	CCC (53)
Tisotumab Vedotin Exocrine Pancreatic Carcinoma	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (53)
Toripalimab Exocrine Pancreatic Carcinoma	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	P2	CCC (53)
Ulixertinib Exocrine Pancreatic Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Zoledronate Exocrine Pancreatic Carcinoma	University of Nebraska	P2	CCC (53)
hcw9218 Exocrine Pancreatic Carcinoma	ImmunityBio, Inc.	P1/2	CCC (52)
Devimistat Exocrine Pancreatic Carcinoma	Northwestern University	P2	CCC (51)
Taselisib Exocrine Pancreatic Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Niraparib Exocrine Pancreatic Carcinoma	OHSU Knight Cancer Institute	P1	CCC (50)
Copanlisib Exocrine Pancreatic Carcinoma	National Cancer Institute (NCI)	P2	CCC (49)
Bet Bromodomain Inhibitor Zen-3694 Exocrine Pancreatic Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (48)
Claudin18.2 Car-T Cells Exocrine Pancreatic Carcinoma	Essen Biotech	P1/2	CCC (48)
Pelareorep Exocrine Pancreatic Carcinoma	Oncolytics Biotech	P1/2	CCC (48)
Tipiracil Exocrine Pancreatic Carcinoma	Emory University	P1/2	CCC (48)
Trifluridine Exocrine Pancreatic Carcinoma	Emory University	P1/2	CCC (48)
Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102 Exocrine Pancreatic Carcinoma	Oncolytics Biotech	P1/2	CCC (48)
Bms-986504 Exocrine Pancreatic Carcinoma	Northwestern University	P1/2	CC (47)
Fluoromisonidazole Exocrine Pancreatic Carcinoma	National Cancer Institute (NCI)	P2	CC (47)
Pertzye Exocrine Pancreatic Carcinoma	Memorial Sloan Kettering Cancer Center	P1/2	CC (47)
Fludarabine Exocrine Pancreatic Carcinoma	Essen Biotech	P1/2	CC (45)
xnw28012 Exocrine Pancreatic Carcinoma	Evopoint Biosciences Inc.	P1/2	CC (45)
Berzosertib Exocrine Pancreatic Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Bosentan Exocrine Pancreatic Carcinoma	City of Hope Medical Center	P1	CC (43)
Certepetide Exocrine Pancreatic Carcinoma	Lisata Therapeutics, Inc.	P1/2	CC (43)
Dostarlimab Exocrine Pancreatic Carcinoma	University of Washington	P1	CC (43)
Guadecitabine Exocrine Pancreatic Carcinoma	University of Southern California	P1	CC (43)
Metformin Exocrine Pancreatic Carcinoma	City of Hope Medical Center	P1	CC (43)
Oatd-02 Exocrine Pancreatic Carcinoma	Molecure S.A.	P1	CC (43)
Catequentinib Exocrine Pancreatic Carcinoma	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	P1	CC (41)
Clsp-5282 Exocrine Pancreatic Carcinoma	Clasp Therapeutics, Inc.	P1	CC (41)
Fludeoxyglucose Exocrine Pancreatic Carcinoma	Jonsson Comprehensive Cancer Center	P1	CC (41)
mgc028 Exocrine Pancreatic Carcinoma	MacroGenics	P1	CC (41)
Modified Vaccinia Virus Ankara Vaccine Expressing P53 Exocrine Pancreatic Carcinoma	City of Hope Medical Center	P1	CC (41)
tqb2858 Exocrine Pancreatic Carcinoma	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	P1	CC (41)
Alectinib Exocrine Pancreatic Carcinoma	OHSU Knight Cancer Institute	Early P1	C (39)
Alpelisib Exocrine Pancreatic Carcinoma	OHSU Knight Cancer Institute	Early P1	C (39)
Anastrozole Exocrine Pancreatic Carcinoma	OHSU Knight Cancer Institute	Early P1	C (39)
Cobimetinib Exocrine Pancreatic Carcinoma	OHSU Knight Cancer Institute	Early P1	C (39)
Entrectinib Exocrine Pancreatic Carcinoma	OHSU Knight Cancer Institute	Early P1	C (39)
Eribulin Exocrine Pancreatic Carcinoma	OHSU Knight Cancer Institute	Early P1	C (39)
Fulvestrant Exocrine Pancreatic Carcinoma	OHSU Knight Cancer Institute	Early P1	C (39)
Hyaluronidase Zzxf Exocrine Pancreatic Carcinoma	OHSU Knight Cancer Institute	Early P1	C (39)
Omeprazole Exocrine Pancreatic Carcinoma	University of Oklahoma	Early P1	C (39)
Vemurafenib Exocrine Pancreatic Carcinoma	OHSU Knight Cancer Institute	Early P1	C (39)
18f-αvβ6-bp Exocrine Pancreatic Carcinoma	Julie L. Sutcliffe, Ph.D	Early P1	C (38)
Codonopsis Exocrine Pancreatic Carcinoma	Zhejiang Provincial People's Hospital	N/A	D (30)

Showing 51 to 100 of 101 assets

PreviousPage 2 of 3Next